Inhibiting the menin–MLL interaction with MI-3 repressed the growth of HCC cell lines that highly express IGF2 by reducing H3K4me3 at the IGF2 promoter, decreasing IGF2 expression, and subsequently inhibiting IGF1R-Akt pathway activation [220]. The gene discussed is KMT2A; the disease is hepatocellular carcinoma.